| Methods |
4‐ to 5‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐114 mm Hg on 2 sequential clinic visits during placebo run‐in; 8‐week double‐blind treatment |
| Participants |
Candesartan 2 mg: n=59(29 males,30 females); mean age=54(10) years; baseline sitting SBP=152(12) mm Hg, DBP=99(4) mm Hg;
Candesartan 4 mg: n=63(44 males,19 females); mean age=55(11) years; baseline sitting SBP=152(17) mm Hg, DBP=100(5) mm Hg;
Candesartan 8 mg: n=60(34 males,26 females); mean age=55(11) years; baseline sitting SBP=154(17) mm Hg, DBP=101(6) mm Hg;
Candesartan 16 mg: n=60(38 males,22 females); mean age=55(11) years; baseline sitting SBP=153(18) mm Hg, DBP=100(5) mm Hg;
Candesartan 32 mg: n=59(41 males,18 females); mean age=55(12) years; baseline sitting SBP=152(17) mm Hg, DBP=100(5) mm Hg;
Placebo: n=64(46 males,18 females); mean age=55(12) years; baseline sitting SBP=154(13) mm Hg, DBP=101(5) mm Hg |
| Interventions |
Candesartan 2 mg once daily;
Candesartan 4 mg once daily;
Candesartan 8 mg once daily;
Candesartan 16 mg once daily;
Candesartan 32 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Least squares mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and 95% CI of change reported, endpoint BP and SD not reported, baseline SD reported; calculated SD of change from 95% CI of change; BP data from Table II, p. 962; Jadad score=3; funding source= Astra Merck Inc. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
